3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Phase 1/2
1
Status
Unknown
1
Completed
1
Sponsor Class
OTHER
1
INDUSTRY
1
Study Type
Interventional
2
Sponsor
Cancer Type
Gastrointestinal
2
Thoracic
1
Breast
1
Conditions
Pancreatic Neoplasms
9
Breast Neoplasms
9
Colorectal Neoplasms
7
Ovarian Neoplasms
5
Sarcoma
4
Prostatic Neoplasms
4
Neoplasms
4
Colonic Neoplasms
4
Melanoma
3
Lymphoma, Non-Hodgkin
3
Lung Neoplasms
3
Glioma
3
Carcinoma, Hepatocellular
3
Wilms Tumor
2
Urinary Bladder Neoplasms
2
Sarcoma, Ewing
2
Rhabdomyosarcoma
2
Rhabdoid Tumor
2
Rectal Neoplasms
2
Osteosarcoma
2
Neuroectodermal Tumors, Primitive, Peripheral
2
Neuroblastoma
2
Multiple Myeloma
2
Medulloblastoma
2
Inflammation
2
Histiocytosis, Langerhans-Cell
2
Hepatoblastoma
2
Hematologic Neoplasms
2
Head and Neck Neoplasms
2
Gastrointestinal Neoplasms
2
Interventions
Oxaliplatin
29
Fluorouracil
25
Leucovorin
20
Capecitabine
18
Irinotecan
17
Surveys and Questionnaires
16
Bevacizumab
14
Cisplatin
12
Blood Specimen Collection
11
Drug Therapy
10
Standard of Care
9
Nivolumab
9
Gemcitabine
9
Cetuximab
7
pembrolizumab
6
Specimen Handling
6
S 1 (combination)
6
Endoscopic Mucosal Resection
6
Cyclophosphamide
6
atezolizumab
5
Sunitinib
5
Radiotherapy
5
Folfox protocol
5
Educational Status
5
Docetaxel
5
fludarabine
4
aldesleukin
4
Radiosurgery
4
Pemetrexed
4
Magnetic Resonance Spectroscopy
4
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Gastrointestinal Neoplasms
×
palbociclib
×
Gastrointestinal
×
Clear all
NCT05039177
2026-03-25
HERKULES-3
Erasca, Inc.
Phase 1/2
Completed
101 enrolled
NCT04591431
2023-10-03
ROME
Fondazione per la Medicina Personalizzata
Phase 2
Unknown
400 enrolled